Special Issue

Challenges in the Diagnosis and Treatment of Parkinson's Disease

Message from the Guest Editors

This Special Issue of *Biomedicines* highlights clinical research addressing the challenges in diagnosing and treating PD while integrating molecular perspectives where relevant. Key areas of interest include the detection of PD subtypes and the identification of diagnostic, progression, and treatment biomarkers, along with their incorporation into clinical workflows. We also focus on the development of early-stage intervention strategies and diagnostic tools, as well as treatment approaches for both early and advanced-stage PD, including the management of drug-induced complications and updates on novel targeted treatments or interventional therapies. Our goal is to inspire further research and clinical innovation, ultimately enhancing diagnostic precision, improving treatment outcomes, and supporting the development of personalized approaches to patient care.

Guest Editors

Dr. Iro Boura

1. School of Medicine, University of Crete, Heraklion, Greece
2. Neurology Department, University General Hospital of Heraklion, Crete, Greece
3. Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

Prof. Dr. Cleanthe Spanaki

1. School of Medicine, University of Crete, Heraklion, Greece
2. Neurology Department, University General Hospital of Heraklion, Crete, Greece

Deadline for manuscript submissions

31 December 2025

MDPI

Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).